JP2010510319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510319A5 JP2010510319A5 JP2009538473A JP2009538473A JP2010510319A5 JP 2010510319 A5 JP2010510319 A5 JP 2010510319A5 JP 2009538473 A JP2009538473 A JP 2009538473A JP 2009538473 A JP2009538473 A JP 2009538473A JP 2010510319 A5 JP2010510319 A5 JP 2010510319A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- quinolin
- ylcyclopropyl
- benzamide
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86084006P | 2006-11-22 | 2006-11-22 | |
| US60/860,840 | 2006-11-22 | ||
| US86145906P | 2006-11-29 | 2006-11-29 | |
| US60/861,459 | 2006-11-29 | ||
| US95723607P | 2007-08-22 | 2007-08-22 | |
| US60/957,236 | 2007-08-22 | ||
| PCT/US2007/085100 WO2008064157A1 (en) | 2006-11-22 | 2007-11-19 | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510319A JP2010510319A (ja) | 2010-04-02 |
| JP2010510319A5 true JP2010510319A5 (enExample) | 2011-01-13 |
| JP5572388B2 JP5572388B2 (ja) | 2014-08-13 |
Family
ID=39166437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538473A Active JP5572388B2 (ja) | 2006-11-22 | 2007-11-19 | キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン |
Country Status (37)
Families Citing this family (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55634B1 (sr) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze |
| RU2008144571A (ru) | 2006-04-12 | 2010-05-20 | Мерк энд Ко., Инк. (US) | Пиридиламидные антагонисты кальциевых каналов т-типа |
| EP2057164A1 (en) * | 2006-08-07 | 2009-05-13 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| PL3034075T3 (pl) | 2006-11-22 | 2019-03-29 | Incyte Holdings Corporation | Imidazotriazyny i imidazopirymidyny jako inhibitory kinaz |
| HUE043732T2 (hu) | 2007-06-13 | 2019-09-30 | Incyte Holdings Corp | Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása |
| RU2010120671A (ru) * | 2007-10-24 | 2011-11-27 | Мерк Шарп Энд Домэ Корп. (Us) | Гетероциклические фениламидные антагонисты кальциевых каналов т-типа |
| WO2009106577A1 (en) | 2008-02-28 | 2009-09-03 | Novartis Ag | Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
| MX393622B (es) | 2008-05-21 | 2025-03-24 | Incyte Corp | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas. |
| WO2010002472A1 (en) * | 2008-07-02 | 2010-01-07 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| FR2933982A1 (fr) * | 2008-07-18 | 2010-01-22 | Sanofi Aventis | Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| JOP20190231A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| MA33032B1 (fr) * | 2009-02-13 | 2012-02-01 | Bayer Schering Pharma Ag | Pyrimidines condensees |
| EP2432555B1 (en) | 2009-05-22 | 2014-04-30 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| KR20120030447A (ko) | 2009-05-22 | 2012-03-28 | 인사이트 코포레이션 | Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴 |
| MX2011013816A (es) | 2009-06-29 | 2012-04-11 | Incyte Corp | Pirimidinonas como inhibidores de pi3k. |
| BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
| EA201200318A1 (ru) | 2009-08-20 | 2012-09-28 | Новартис Аг | Гетероциклические оксимы |
| WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| SI3511330T1 (sl) | 2009-12-31 | 2021-01-29 | Hutchison Medipharma Limited | Sintetična umetna spojina uporabna v pripravi triazolopiridinskih zaviralcev c-Met |
| CN102812027B (zh) | 2010-02-03 | 2015-01-07 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
| TWI531572B (zh) | 2010-03-10 | 2016-05-01 | 英塞特公司 | 作為ｊａｋ１抑制劑之哌啶－４－基三亞甲亞胺衍生物 |
| US8518945B2 (en) * | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| MX2012011941A (es) * | 2010-04-14 | 2013-08-27 | Array Biopharma Inc | Imidazo [1, 2-c] pirimidinas 5, 7-substituidas como inhibidores de jak cinasas. |
| AU2011254242B2 (en) * | 2010-05-17 | 2015-10-29 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3H-imidazo[4,5-b]pyridine and 3,5- disubstitued -3H-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| US20110288107A1 (en) | 2010-05-21 | 2011-11-24 | Bhavnish Parikh | Topical formulation for a jak inhibitor |
| PH12013501001A1 (en) | 2010-11-19 | 2019-09-02 | Incyte Holdings Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| CN103298468A (zh) | 2011-02-01 | 2013-09-11 | 协和发酵麒麟株式会社 | 稠环杂环衍生物 |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| AU2012273164B2 (en) | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| KR20230038593A (ko) | 2011-09-02 | 2023-03-20 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| CN103030654A (zh) * | 2011-10-09 | 2013-04-10 | 济南赛文医药技术有限公司 | 一种小分子c-Met蛋白激酶抑制剂 |
| PH12014500730A1 (en) * | 2011-10-12 | 2018-01-17 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| MX371119B (es) | 2012-04-03 | 2020-01-17 | Novartis Ag | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. |
| AU2013243737B2 (en) | 2012-04-03 | 2016-06-30 | Novartis Ag | Tyrosine kinase inhibitor combinations and their use |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| EP3176170B1 (en) | 2012-06-13 | 2018-11-14 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| ES2901712T3 (es) * | 2012-08-16 | 2022-03-23 | Novartis Ag | Combinación de un inhibidor de pi3k y un inhibidor de c-met. |
| CR20190073A (es) | 2012-11-15 | 2019-04-25 | Incyte Holdings Corp | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| SMT202100694T1 (it) | 2013-03-06 | 2022-03-21 | Incyte Holdings Corp | Procedimenti e intermedi per produrre un inibitore di jak |
| CN105968115B (zh) * | 2013-04-17 | 2018-11-09 | 上海医药集团股份有限公司 | 喹啉类化合物、其制备方法、中间体、药物组合物和应用 |
| WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| CA2920108C (en) | 2013-08-07 | 2022-07-05 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| GB201321736D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321732D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| DK3105218T3 (da) | 2014-02-13 | 2019-11-04 | Incyte Corp | Cyclopropylaminer som lsd1-inhibitorer |
| TW201613860A (en) | 2014-02-13 | 2016-04-16 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
| TWI720451B (zh) | 2014-02-13 | 2021-03-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
| EP3116909B1 (en) | 2014-03-14 | 2019-11-13 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| EP3122358B1 (en) | 2014-03-26 | 2020-12-16 | Astex Therapeutics Ltd. | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| JP6770946B2 (ja) | 2014-07-25 | 2020-10-21 | ノバルティス アーゲー | ２−フルオロ−ｎ−メチル−４−［７−（キノリン−６−イルメチル）イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの錠剤 |
| US10195208B2 (en) * | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
| AU2015314756A1 (en) | 2014-09-13 | 2017-03-16 | Novartis Ag | Combination therapies of alk inhibitors |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| MX373169B (es) * | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| TWI713497B (zh) * | 2015-02-26 | 2020-12-21 | 南韓商愛思開生物製藥股份有限公司 | 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物 |
| AU2016222556B2 (en) | 2015-02-27 | 2020-08-27 | Incyte Holdings Corporation | Salts of Pl3K inhibitor and processes for their preparation |
| JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
| PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
| KR20170139064A (ko) | 2015-04-21 | 2017-12-18 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 이미다조 이소인돌 유도체, 이의 제조방법 및 이의 의학적 용도 |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016190630A1 (en) | 2015-05-22 | 2016-12-01 | Chong Kun Dang Pharmaceutical Corp. | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same |
| PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
| CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| UA126277C2 (uk) | 2015-08-12 | 2022-09-14 | Інсайт Корпорейшн | Солі інгібітору lsd1 |
| AU2016369623A1 (en) * | 2015-12-17 | 2018-06-28 | Novartis Ag | Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof |
| EP4424322A3 (en) | 2015-12-17 | 2025-04-16 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| WO2017129801A1 (en) | 2016-01-27 | 2017-08-03 | Universität Zürich | Use of gabaa receptor modulators for treatment of itch |
| MX2018011792A (es) * | 2016-03-28 | 2019-07-04 | Incyte Corp | Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam). |
| MA44725A (fr) | 2016-04-22 | 2019-02-27 | Incyte Corp | Formulations d'un inhibiteur de lsd1 |
| WO2017202719A1 (en) * | 2016-05-23 | 2017-11-30 | Boehringer Ingelheim International Gmbh | New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| CN106496000A (zh) * | 2016-10-19 | 2017-03-15 | 蚌埠学院 | 一种3‑氟‑4‑溴‑苯乙酮的合成方法 |
| ES2881395T3 (es) | 2016-12-22 | 2021-11-29 | Calithera Biosciences Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3687996B1 (en) | 2017-09-27 | 2021-11-03 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| CN111936136B (zh) | 2017-11-14 | 2024-07-05 | 儿童医学中心公司 | 新咪唑并嘧啶化合物及其用途 |
| KR102775718B1 (ko) * | 2017-11-14 | 2025-03-06 | 칠드런'즈 메디컬 센터 코포레이션 | 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도 |
| WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| EP3746429B1 (en) | 2018-01-30 | 2022-03-09 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| CN110526916B (zh) * | 2018-05-23 | 2021-07-13 | 海创药业股份有限公司 | 氘代Capmatinib化合物及其用途 |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| MX2020012826A (es) | 2018-06-01 | 2021-03-09 | Incyte Corp | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). |
| CN108530337B (zh) * | 2018-06-25 | 2020-11-03 | 南华大学 | 一种可选择性抑制胃癌细胞的吲哚酰胺类化合物 |
| DK3813800T3 (da) | 2018-06-29 | 2025-06-02 | Incyte Corp | Formuleringer af en axl/mer-hæmmer |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| WO2020069418A1 (en) * | 2018-09-28 | 2020-04-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1/clk and uses thereof |
| JP7414827B2 (ja) * | 2018-12-20 | 2024-01-16 | インサイト・コーポレイション | アクチビン受容体様キナーゼ－２の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物 |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| AU2019407426A1 (en) | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| IL293834A (en) | 2019-12-20 | 2022-08-01 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| WO2021173476A1 (en) | 2020-02-24 | 2021-09-02 | The Trustees Of Columbia University In The City Of New York | Compounds, pharmaceutical formulations, and methods for treatment of cancer |
| PH12022552347A1 (en) | 2020-03-06 | 2024-01-29 | Incyte Corp | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN111825678A (zh) * | 2020-06-05 | 2020-10-27 | 连庆泉 | 一种卡马替尼的制备方法 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| WO2022007752A1 (zh) * | 2020-07-06 | 2022-01-13 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| CN113896732B (zh) * | 2021-10-13 | 2023-09-12 | 沈阳红旗制药有限公司 | 抗癌药物卡马替尼的制备方法及其应用 |
| WO2023249994A1 (en) * | 2022-06-22 | 2023-12-28 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
| CN116903627B (zh) * | 2023-05-15 | 2024-01-16 | 云白药征武科技(上海)有限公司 | 一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1411859A (en) | 1920-12-08 | 1922-04-04 | Marchand Robert | Process for preparing hydrate of terpin |
| US2837520A (en) * | 1955-05-26 | 1958-06-03 | Ind Chimica Profarmaco S R L | Fluorescent materials on the basis of tetrazoindenes |
| US4209621A (en) | 1979-04-27 | 1980-06-24 | American Cyanamid Company | (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines |
| US4405619A (en) | 1981-09-02 | 1983-09-20 | Diamond Shamrock Corporation | Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines |
| DE3311753A1 (de) | 1983-03-31 | 1984-10-04 | Hoechst Ag, 6230 Frankfurt | Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung - |
| JPS6337347A (ja) | 1986-08-01 | 1988-02-18 | Fuji Photo Film Co Ltd | 直接ポジカラ−画像形成方法 |
| JPS63199347A (ja) | 1987-02-14 | 1988-08-17 | Konica Corp | 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料 |
| JPS63310891A (ja) | 1987-06-12 | 1988-12-19 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリダジン化合物 |
| US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| JPH0313934A (ja) | 1989-06-12 | 1991-01-22 | Konica Corp | ハロゲン化銀写真感光材料 |
| IL96432A0 (en) | 1989-11-30 | 1991-08-16 | Schering Ag | Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives |
| JP2664264B2 (ja) | 1990-02-15 | 1997-10-15 | 富士写真フイルム株式会社 | ハロゲン化銀写真乳剤及びこれを用いた写真感光材料 |
| FR2662163A1 (fr) | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
| JPH04251243A (ja) | 1991-01-09 | 1992-09-07 | Konica Corp | ハロゲン化銀写真感光材料 |
| FR2671551B1 (fr) | 1991-01-15 | 1993-03-12 | Adir | Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5232618A (en) | 1991-09-30 | 1993-08-03 | E. I. Du Pont De Nemours And Company | Substantially constant boiling compositions of difluoromethane and trifluoroethane or perfluoroethane |
| JPH05232618A (ja) | 1992-02-21 | 1993-09-10 | Konica Corp | ハロゲン化銀写真感光材料 |
| DE4309285A1 (de) | 1993-03-23 | 1994-09-29 | Boehringer Ingelheim Kg | Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung |
| SK179899A3 (en) * | 1997-07-03 | 2001-12-03 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| ES2137113B1 (es) | 1997-07-29 | 2000-09-16 | Almirall Prodesfarma Sa | Nuevos derivados de triazolo-piridazinas heterociclicos. |
| DE19734311A1 (de) | 1997-08-08 | 1999-02-11 | Bosch Gmbh Robert | Anordnung zur Übertragung optischer Signale mit Ersatzschaltungswirkung |
| JP4251243B2 (ja) | 1998-11-26 | 2009-04-08 | 株式会社日立メディコ | 領域拡張装置 |
| JP4025468B2 (ja) * | 1999-07-29 | 2007-12-19 | 三井化学株式会社 | 有機電界発光素子 |
| CZ20012494A3 (cs) | 1999-11-10 | 2001-10-17 | Ortho-Mcneil Pharmaceutical, Inc. | Substituované 2-aryl-3-(heteroaryl)-imidazo[1,2-a]Pyrimidiny, způsob přípravy těchto sloučenin a farmaceutické kompozice obsahující tyto sloučeniny |
| MXPA02004735A (es) | 1999-11-12 | 2003-01-28 | Orive Javier Uhthoff | Compuestos heteroaromaticos, biciclicos y triciclicos. |
| DE10010067A1 (de) * | 2000-03-02 | 2001-09-06 | Bayer Ag | Neue Imidazotriazinone und ihre Verwendung |
| AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| WO2002038568A1 (en) | 2000-11-10 | 2002-05-16 | Merck Sharp & Dohme Limited | Imidazo-triazine derivatives as ligands for gaba receptors |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| EE200300437A (et) | 2001-03-09 | 2004-02-16 | Pfizer Products Inc. | Triasolopüridiinid kui põletikuvastased ained |
| GB0107751D0 (en) | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
| CA2448076A1 (en) | 2001-05-24 | 2002-11-28 | Masahiko Hayakawa | 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives |
| DE10130167A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| EP1481977A4 (en) | 2002-03-01 | 2006-02-01 | Astellas Pharma Inc | NITROGENIC HETEROCYCLIC COMPOUND |
| WO2003080621A1 (en) | 2002-03-19 | 2003-10-02 | Merck & Co., Inc. | Process and intermediates to substituted imidazopyrimidines |
| US6790852B2 (en) | 2002-04-18 | 2004-09-14 | Hoffmann-La Roche Inc. | 2-(2,6-dichlorophenyl)-diarylimidazoles |
| GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| BR0313961A (pt) | 2002-08-30 | 2005-07-19 | Pfizer Prod Inc | Processos e intermediários para preparar triazolo-piridinas |
| US6784297B2 (en) | 2002-09-04 | 2004-08-31 | Kopran Limited | Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate |
| CA2510534C (en) | 2002-12-18 | 2011-09-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| GB0303910D0 (en) * | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| DK2476667T3 (da) | 2003-02-26 | 2014-09-15 | Sugen Inc | Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| CA2529558A1 (en) | 2003-07-01 | 2005-01-13 | Astellas Pharma Inc. | Agent inducing increase in bone mass |
| MXPA06000091A (es) | 2003-07-02 | 2006-04-07 | Sugen Inc | Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met. |
| MXPA06000276A (es) | 2003-07-02 | 2006-04-07 | Sugen Inc | Indolinona hidrazidas como inhibidores de c-met. |
| US7037909B2 (en) | 2003-07-02 | 2006-05-02 | Sugen, Inc. | Tetracyclic compounds as c-Met inhibitors |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| ES2298798T3 (es) | 2003-07-30 | 2008-05-16 | Laboratorios S.A.L.V.A.T., S.A. | Imidazopirimidinas sustituidas para la prevencion y el tratamiento del cancer. |
| AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| WO2005040345A2 (en) | 2003-09-24 | 2005-05-06 | Vertex Pharmceuticals Incorporated | 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| PL2392565T3 (pl) | 2003-09-26 | 2014-08-29 | Exelixis Inc | Modulatory c-Met i sposoby stosowania |
| US7144889B2 (en) | 2003-10-16 | 2006-12-05 | Hoffman-La Roche Inc. | Triarylimidazoles |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
| EA011402B1 (ru) | 2004-01-23 | 2009-02-27 | Эмджен Инк. | Азотсодержащие гетероциклические производные и их фармацевтические применения |
| CN1922183B (zh) | 2004-02-18 | 2010-05-26 | 万有制药株式会社 | 含氮的稠合杂芳环衍生物 |
| AR048518A1 (es) * | 2004-04-02 | 2006-05-03 | Osi Pharm Inc | Inhibidores heterobiciclicos de proteina quinasas sustituidos con anillos 6,6 -biciclicos |
| US20050277650A1 (en) | 2004-04-20 | 2005-12-15 | Sundaram Venkataraman | Process for preparing aripirazole hydrate |
| CA2564355C (en) | 2004-05-07 | 2012-07-03 | Amgen Inc. | Protein kinase modulators and method of use |
| WO2005121125A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| EP1773826A4 (en) | 2004-07-02 | 2009-06-03 | Exelixis Inc | MODULATORS OF C-MET AND THEIR METHOD OF USE |
| AR053090A1 (es) * | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
| MX2007001127A (es) * | 2004-07-27 | 2007-07-11 | Sgx Pharmaceuticals Inc | Moduladores de pirrolo-piridina cinasa. |
| ES2341351T3 (es) | 2004-08-26 | 2010-06-18 | Pfizer, Inc. | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina cinasas. |
| JP2008516962A (ja) | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
| US8030327B2 (en) * | 2004-11-08 | 2011-10-04 | Mds K.K. | Fused imidazole derivative |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| US7459564B2 (en) | 2005-01-13 | 2008-12-02 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor XIa inhibitors |
| CA2606017A1 (en) | 2005-05-12 | 2006-11-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP2009500451A (ja) | 2005-07-11 | 2009-01-08 | スミスクライン ビーチャム コーポレーション | ピラノピリジン化合物 |
| WO2007015866A2 (en) * | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
| US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| AU2006320580B2 (en) | 2005-11-30 | 2011-06-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| WO2007075567A1 (en) | 2005-12-21 | 2007-07-05 | Janssen Pharmaceutica, N.V. | Triazolopyridazines as tyrosine kinase modulators |
| US8114874B2 (en) | 2005-12-23 | 2012-02-14 | Ariad Pharmaceuticals, Inc. | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
| WO2007096764A2 (en) * | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| EP2057164A1 (en) | 2006-08-07 | 2009-05-13 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| US8071581B2 (en) | 2006-10-23 | 2011-12-06 | Sgx Pharmaceuticals, Inc. | Triazolopyridazine protein kinase modulators |
| EP2086979B1 (en) | 2006-11-06 | 2015-06-03 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| PL3034075T3 (pl) * | 2006-11-22 | 2019-03-29 | Incyte Holdings Corporation | Imidazotriazyny i imidazopirymidyny jako inhibitory kinaz |
| BRPI0812360A2 (pt) | 2007-05-21 | 2015-01-27 | Sgx Pharmaceuticals Inc | Compostos moduladores de quinase heterocíclica e método de modulação da atividade de uma proteína tirosina quinase |
| MX393622B (es) | 2008-05-21 | 2025-03-24 | Incyte Corp | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas. |
| CN102812027B (zh) | 2010-02-03 | 2015-01-07 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
| US8901323B2 (en) | 2011-05-06 | 2014-12-02 | Takasago International Corporation | Ruthenium-diamine complex and method for producing optically active compound |
-
2007
- 2007-11-19 PL PL15191241T patent/PL3034075T3/pl unknown
- 2007-11-19 EP EP18182215.6A patent/EP3443958A1/en active Pending
- 2007-11-19 JP JP2009538473A patent/JP5572388B2/ja active Active
- 2007-11-19 EA EA201691862A patent/EA032254B1/ru active IP Right Revival
- 2007-11-19 KR KR1020097013022A patent/KR101532256B1/ko active Active
- 2007-11-19 RS RS20160017A patent/RS54510B1/sr unknown
- 2007-11-19 AU AU2007323725A patent/AU2007323725B2/en active Active
- 2007-11-19 KR KR1020147033803A patent/KR101588583B1/ko active Active
- 2007-11-19 PL PL07864592T patent/PL2099447T3/pl unknown
- 2007-11-19 DK DK07864592.6T patent/DK2099447T3/da active
- 2007-11-19 MY MYPI2013000862A patent/MY188338A/en unknown
- 2007-11-19 SI SI200731739T patent/SI2497470T1/sl unknown
- 2007-11-19 CN CN201310141352.4A patent/CN103288833B/zh active Active
- 2007-11-19 NZ NZ577127A patent/NZ577127A/en unknown
- 2007-11-19 CA CA2669991A patent/CA2669991C/en active Active
- 2007-11-19 BR BRPI0719333-5A patent/BRPI0719333A2/pt active IP Right Grant
- 2007-11-19 HU HUE12158715A patent/HUE026659T2/en unknown
- 2007-11-19 ES ES15191241.7T patent/ES2689444T3/es active Active
- 2007-11-19 MX MX2009005144A patent/MX2009005144A/es active IP Right Grant
- 2007-11-19 RS RS20181200A patent/RS57741B1/sr unknown
- 2007-11-19 WO PCT/US2007/085100 patent/WO2008064157A1/en not_active Ceased
- 2007-11-19 RS RS20130041A patent/RS52677B/sr unknown
- 2007-11-19 CN CN2007800503102A patent/CN101641093B/zh active Active
- 2007-11-19 EA EA200970501A patent/EA026126B1/ru unknown
- 2007-11-19 SI SI200731149T patent/SI2099447T1/sl unknown
- 2007-11-19 PT PT121587158T patent/PT2497470E/pt unknown
- 2007-11-19 HR HRP20130106TT patent/HRP20130106T1/hr unknown
- 2007-11-19 PT PT78645926T patent/PT2099447E/pt unknown
- 2007-11-19 PT PT15191241T patent/PT3034075T/pt unknown
- 2007-11-19 NO NO20200077A patent/NO346024B1/no unknown
- 2007-11-19 US US11/942,130 patent/US7767675B2/en active Active
- 2007-11-19 EP EP12158715.8A patent/EP2497470B8/en active Active
- 2007-11-19 PL PL12158715T patent/PL2497470T3/pl unknown
- 2007-11-19 ES ES12158715.8T patent/ES2560435T3/es active Active
- 2007-11-19 EP EP15191241.7A patent/EP3034075B1/en active Active
- 2007-11-19 GE GEAP200711325A patent/GEP20125658B/en unknown
- 2007-11-19 EP EP07864592A patent/EP2099447B1/en active Active
- 2007-11-19 ES ES07864592T patent/ES2398843T3/es active Active
- 2007-11-19 MY MYPI20092064A patent/MY188335A/en unknown
- 2007-11-19 ME MEP-2013-35A patent/ME01507B/me unknown
- 2007-11-19 ME MEP-2016-13A patent/ME02372B/me unknown
- 2007-11-19 DK DK15191241.7T patent/DK3034075T3/en active
- 2007-11-19 SI SI200732055T patent/SI3034075T1/sl unknown
- 2007-11-19 DK DK12158715.8T patent/DK2497470T3/en active
- 2007-11-19 LT LTEP15191241.7T patent/LT3034075T/lt unknown
- 2007-11-21 AR ARP070105176A patent/AR066142A1/es active IP Right Grant
- 2007-11-22 TW TW096144319A patent/TWI429432B/zh active
- 2007-11-22 CL CL200703341A patent/CL2007003341A1/es unknown
-
2009
- 2009-05-12 IL IL198716A patent/IL198716A/en active IP Right Grant
- 2009-05-18 NO NO20091924A patent/NO344399B1/no active Protection Beyond IP Right Term
- 2009-06-08 CR CR10841A patent/CR10841A/es unknown
- 2009-06-10 CO CO09060491A patent/CO6210810A2/es active IP Right Grant
- 2009-06-11 EC EC2009009400A patent/ECSP099400A/es unknown
-
2010
- 2010-06-10 US US12/813,148 patent/US8461330B2/en active Active
-
2013
- 2013-02-04 CY CY20131100098T patent/CY1116763T1/el unknown
- 2013-05-16 US US13/895,799 patent/US20130324515A1/en not_active Abandoned
-
2016
- 2016-01-12 CY CY20161100026T patent/CY1117108T1/el unknown
- 2016-01-25 HR HRP20160077TT patent/HRP20160077T1/hr unknown
- 2016-02-05 US US15/016,841 patent/US9944645B2/en active Active
- 2016-02-23 IL IL244244A patent/IL244244B/en active IP Right Grant
- 2016-12-16 HK HK16114386.5A patent/HK1225978B/en unknown
-
2018
- 2018-03-20 US US15/925,996 patent/US10738052B2/en active Active
- 2018-10-05 HR HRP20181622TT patent/HRP20181622T1/hr unknown
- 2018-10-22 CY CY20181101082T patent/CY1121021T1/el unknown
-
2019
- 2019-06-07 NO NO20190709A patent/NO344864B1/no unknown
-
2020
- 2020-06-23 US US16/909,686 patent/US11261191B2/en active Active
- 2020-08-25 IL IL276928A patent/IL276928B/en unknown
-
2021
- 2021-07-15 IL IL284889A patent/IL284889B2/en unknown
-
2022
- 2022-01-13 US US17/575,371 patent/US12084449B2/en active Active
- 2022-12-12 LU LU00293C patent/LUC00293I2/en unknown
- 2022-12-13 LT LTPA2022527C patent/LTC2099447I2/lt unknown
- 2022-12-13 NO NO2022057C patent/NO2022057I1/no unknown
- 2022-12-14 HU HUS2200052C patent/HUS2200052I1/hu unknown
- 2022-12-15 FR FR22C1060C patent/FR22C1060I2/fr active Active
- 2022-12-16 NL NL301209C patent/NL301209I2/nl unknown
- 2022-12-16 CY CY2022037C patent/CY2022037I2/el unknown
-
2024
- 2024-08-08 US US18/798,506 patent/US20250223291A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510319A5 (enExample) | ||
| ME01507B (me) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
| JP2021502356A5 (enExample) | ||
| US9284298B2 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| JP2019523233A5 (enExample) | ||
| JP2013523884A5 (enExample) | ||
| JP2016517878A5 (enExample) | ||
| HRP20231614T1 (hr) | Spojevi pirolotriazina kao tam inhibitori | |
| JP2019512482A5 (enExample) | ||
| JP2018044008A5 (enExample) | ||
| JP2016522246A5 (enExample) | ||
| JP2017530185A5 (enExample) | ||
| JP2018500376A5 (enExample) | ||
| JP2009524589A5 (ja) | 置換されたイソキノリン−１，３（２ｈ，４ｈ）−ジオン、１−チオキソ−１，４−ジヒドロ−２ｈ−イソキノリン−３−オン、および１，４−ジヒドロ−３（２ｈ）−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用 | |
| JP2017052805A5 (enExample) | ||
| JP2016523911A5 (enExample) | ||
| JP2016523976A5 (enExample) | ||
| SI2797918T1 (en) | Bromodomain inhibitors | |
| JP2016528298A5 (enExample) | ||
| JP2016510035A5 (enExample) | ||
| JP2009525978A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| US11529350B2 (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |